Pulmovant
Cardiometabolic Therapeutics · Prescription Drugs
4open roles
1-10people
6cities with offices
15technologies in use
Jobs
≈ $77k – $168k per year (Estimated) · Remote (United States) · 4+ years exp · Bachelor's Degree
GMP
MedTech
CAPA
Apply
≈ $171k – $293k per year (Estimated) · Remote (United States) · 15+ years exp · PhD
GMP
Apply
≈ $176k – $301k per year (Estimated) · Remote (United States) · 5+ years exp · Bachelor's Degree
Smartsheet
Microsoft Project
SharePoint
Life Sciences
GMP
Apply
≈ $174k – $298k per year (Estimated) · Remote (United States) · 15+ years exp · PhD
SharePoint
Life Sciences
Veeva
Apply
Visa sponsorship
1
H-1B filings in 12 months
$213k
Median offered salary
9
Open roles in United States
Who they sponsor
Data scientists
1
In the register as Pulmovant Inc., Waltham, MA
Other sponsors in the same field
Eli Lilly and Company 420 filings
Amgen 372 filings
Bristol Myers Squibb 218 filings
Novo Nordisk 39 filings
See 9 open roles Alert me
US Department of Labor · latest filing Nov 26, 2025 · Visa details by country
Growth
Hiring Momentum
42/100
Stable
Open positions
9
1 opened / 3 closed in 30 days
Median time-to-fill
33 days
faster than 40% of the market
ATS activity
Every ~5 hours
Today
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Field & Service
63% ▼
Biotech
25% ▲
Administrative
6% ▲
Public Policy
6% ▼
Activity Timeline
Added CDISC to stack
Oct 2026
Added Veeva to stack
Oct 2026
Added ICH Guidelines to stack
Oct 2026
Added Design of Experiments to stack
Oct 2026
Added JMP to stack
Oct 2026
Added GMP to stack
Oct 2026
Added CAPA to stack
Oct 2026
Added Mandiant capa to stack
Oct 2026
Added Microsoft Project to stack
Oct 2026
Added Smartsheet to stack
Sep 2026
Added Python to stack
Sep 2026
Added Git to stack
Sep 2026
Tech stack
Technologies named in job postings at Pulmovant over the last 12 months, by layer, with the share of postings for each.
Technologies in use
15
Postings analysed
12
Stack modernity
75/100AI adopter
Languages
SAS17%
Python8%
Databases
Oracle8%
Cloud & platforms
GCP42%
AI & ML
ChatGPT8%
Claude8%
Sign in to see how your skills match this stack
Sign In
Full Pulmovant tech stack
15 technologies · by team · pay by technology · changes · similar stacks
News
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3...
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascu...
Read more
Report
Pulmovant Announces Positive Results from PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) and Unveils Ongoing Phase 3 PHrontier Study
PHocus met its primary endpoint, demonstrating a clinically meaningful and statistically significant placebo-adjusted reduction in pulmonary vascular resistance (PVR) of -56.3% (p
Read more
Report
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026...
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of pati...
Read more
Report
Pulmovant to Present Topline Results from the Phase 2 PHocus Study of Mosliciguat in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) at the ERS Congress 2026 on Tuesday, September 8, 2026
WALTHAM, Mass., Sept. 06, 2026 (GLOBE NEWSWIRE) -- Pulmovant, a clinical-stage biotechnology company committed to transforming the lives of patients with pulmonary diseases, and a Roivant (Nasdaq: ROIV) company, today announced that results from the Phase
Read more
Report
Report
Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics
Three Phase 1 studies support once-daily inhaled administration of mosliciguat with no evidence of serious systemic side effects Results informed the ongoing Phase 2 PHocus study of mosliciguat for the treatment of pulmonary hypertension associated with i
Read more
Report
Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress - Company Announcement - FT.com
The latest company information, including net asset values, performance, holding & sectors weighting, changes in voting rights, and directors and dealings.
Read more
Report
Offices
Where the company hires and what each office is for
Cities
6
Hiring now
0
Countries
2
Loading the map
Headquarters
Builds here
Office with open vacancies
No open vacancies right now Tap a pin for the office
Waltham
United States
HQ
Pulmovant
303 Wyman St, Suite 300, Waltham, MA 02451
New York
United States
Regional office
Roivant Sciences
Philadelphia
United States
Regional office
Spirovant Sciences
Basel
Switzerland
Regional office
Emavant
Princeton
United States
Regional office
Princeton, NJ
Boston
United States
Regional office
Roivant Discovery